Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can you name the year of keytruda's maiden fda nod?Cresemba 186 mg capsule?How much does ofev cost?Alclometasone shortage?Lixisenatide class action?
See the DrugPatentWatch profile for Lixisenatide
What is Lixisenatide's patent status, and who is involved in its development? Lixisenatide is a medication used for the treatment of type 2 diabetes [1]. It works as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the action of the naturally occurring GLP-1 hormone. Who developed Lixisenatide? Lixisenatide was developed by Eli Lilly and Company, in collaboration with the French pharmaceutical company Servier [2]. What are the key patent holders for Lixisenatide? The original patent for Lixisenatide expired in various regions worldwide. Although its original patent held by Eli Lilly in the United States is expired, the drug still faces various barriers, including extended patents and marketing exclusivity. For example, Eli Lilly had filed for an additional patent extension in the US for the method of use covering Lixisenatide in the treatment of chronic kidney disease (CKD) and heart failure [3]. DrugPatentWatch.com has detailed information on the patent status and history of Lixisenatide [4]. What are implications of these patents on market competition and availability? As patents on Lixisenatide expire or remain in force, manufacturers can apply for approval from regulatory agencies to market their generic versions of the drug. This competition can drive down prices, increase accessibility, and offer alternative treatment options for patients [5]. DrugPatentWatch.com tracks patent expiration dates for numerous medications, including Lixisenatide, providing essential information for pharmaceutical manufacturers and healthcare professionals. Sources: [1] https://en.wikipedia.org/wiki/Lixisenatide [2] https://www.lilly.com/newsroom/news/lilly-and-servier-enter-global-licensing-agreement-for-the-development-and-commercialization-of-lixisenatide-in-type-2-diabetes [3] https://www.drugpatentwatch.com/US/US20170201173 [4] https://www.drugpatentwatch.com/US/US7943783 [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291453/#:~:text=Generic%20pharmaceuticals%20have%20become,the%20same%20therapeutic%20action.
Other Questions About Lixisenatide :